AdaptHealth (NASDAQ:AHCO – Free Report) had its target price reduced by Robert W. Baird from $16.00 to $14.00 in a report ...

The company posted a triple whiff, coming in under pundit projections for revenue, profitability, and top-line guidance.

Leerink Partners analyst Whit Mayo has reiterated their bullish stance on AHCO stock, giving a Buy rating yesterday. Whit Mayo has given his ...

Baird analyst Eric Coldwell maintained AdaptHealth with an Outperform and lowered the price target from $16 to $14. Canaccord Genuity analyst Richard Close maintained the stock with a Buy and cut the ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Looking ahead, revenue ...

On Tuesday, Adapthealth Corp (AHCO) stock saw a decline, ending the day at $9.18 which represents a decrease of $-0.97 or -9.56% from the prior close of $10.15. The stock opened at $8.94 and touched a ...

Adapthealth ( (AHCO) ) has released its Q3 earnings. Here is a breakdown of the information Adapthealth presented to its investors. AdaptHealth ...

AdaptHealth reported third quarter net revenue of $805.9 million compared to $804 million, an increase of 0.2% year over year.

Gary Sheehan has started a new role at AdaptHealth as general manager, senior vice president, of diabetes. “I am looking ...

Bearish flow noted in AdaptHealth (AHCO) with 3,058 puts trading, or 1.2x expected. Most active are Dec-24 7.5 puts and Dec-24 10 puts, with total volume in those strikes near 2,800 contracts.

AdaptHealth published its third-quarter results early that morning, and probably wishes it had taken a sick day for the remainder. Revenue inched up marginally on a year-over-year basis to just ...